ACRS Aclaris Therapeutics, Inc. Common Stock

Data is currently not available
ACRS
Data is currently not available
Access your previously viewed quotes
Your previously viewed symbols will appear here as you browse the site.
Previously Viewed
  • Data is currently not available
Quotes and Chart Key Data News Options Profile Filings - Ownership

ACRS

See real-time trades
SELECT THE TIMEFRAME :
Data is currently not available
Previous
Close  
See Pre-Market Trading See After-Hours Trading

Links for Quotes and Charts

Summary Data

Data is currently not available

Links for Key Data

Earnings Per Share

Estimated Reported
Data is currently not available
Estimated EPS 1.00
Reported EPS: 1.00
SEE ALL REVENUE AND Earnings Per Share

Dividend History

  • ACRS Ex-Dividend Date  
  • ACRS Dividend Yield  %
  • ACRS Annual Dividend $ 
  • ACRS Payout Ratio  %
Data is currently not available
 
   
See Full Dividend History

Short Interest

Data is currently not available
 
   
See Full Short Interest History

News Quick Links

Published
Oct 25, 2019
US Markets

Health Care Sector Update for 10/25/2019: ACRS, SENS, HUM, UHS, JNJ, PFE, ABT, MRK, AMGN

Published
Oct 25, 2019
Published
Oct 11, 2019
US Markets

Health Care Sector Update for 10/11/2019: CLVS,GERN,ACRS,HEXO,HEXO.TO

Published
Oct 11, 2019
Published
Oct 11, 2019
US Markets

Health Care Sector Update for 10/11/2019: GERN,ACRS,HEXO

Published
Oct 11, 2019
Published
Oct 11, 2019
US Markets

Health Care Sector Update for 10/11/2019: ACRS, GERN, GILD, GLPG, JNJ, PFE, ABT, MRK, AMGN

Published
Oct 11, 2019
See More
See All News

News

Published
Nov 12, 2019

Aclaris Therapeutics to Present at Upcoming Investor Conferences

Published
Nov 12, 2019
Published
Nov 7, 2019

Aclaris Therapeutics Reports Third Quarter 2019 Financial Results and Provides Business Highlights and an Update on R&D Programs

Published
Nov 7, 2019
Published
Oct 31, 2019

Aclaris Therapeutics to Announce Third Quarter 2019 Financial Results on November 7, 2019

Published
Oct 31, 2019
Published
Oct 24, 2019

Aclaris Therapeutics’ A-101 45% Topical Solution Meets Primary and All Secondary Efficacy Endpoints in Second Successful Pivotal Phase 3 Clinical Trial for the Treatment of Common Warts (THWART-1)

Published
Oct 24, 2019
Published
Oct 10, 2019

Aclaris Therapeutics Announces Divestiture of RHOFADE®

Published
Oct 10, 2019
Published
Oct 8, 2019

Aclaris Therapeutics Files Patent Infringement Lawsuit Against Taro Pharmaceuticals, Inc. for Filing an ANDA for a Generic Version of RHOFADE® (oxymetazoline hydrochloride) cream, 1%

Published
Oct 8, 2019
Published
Sep 26, 2019

SHAREHOLDER ALERT:  Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Aclaris Therapeutics Inc. of Class Action Lawsuit and Upcoming Deadline - ACRS

Published
Sep 26, 2019
Published
Sep 17, 2019

Thinking about buying stock in Aclaris Therapeutics, Alder Biopharmaceuticals, Capricor Therapeutics, Canopy Growth, or ConocoPhillips?

Published
Sep 17, 2019
Published
Sep 17, 2019

Aclaris Therapeutics to Hold R&D Day

Published
Sep 17, 2019
Published
Sep 16, 2019

Aclaris Therapeutics’ A-101 45% Topical Solution Meets Primary and All Secondary Efficacy Endpoints in Pivotal Phase 3 Trial for the Treatment of Common Warts (THWART-2)

Published
Sep 16, 2019
Published
Aug 24, 2019

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Aclaris Therapeutics, Inc. - ACRS

Published
Aug 24, 2019
Published
Aug 2, 2019

ROSEN, A HIGHLY RANKED LAW FIRM, Announces Filing of Securities Class Action Lawsuit Against Aclaris Therapeutics, Inc.; Encourages Investors with Losses in Excess of $100K to Contact the Firm - ACRS

Published
Aug 2, 2019
Published
Jul 31, 2019

LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Aclaris Therapeutics, Inc. To Contact The Firm

Published
Jul 31, 2019
Published
Jul 26, 2019

Lifshitz & Miller LLP Announces Investigation of Acer Therapeutics Inc., Aclaris Therapeutics, Inc., Ideanomics, Inc., L Brands, Inc., Marriott International, Inc., NRC Group Holdings Corp., Omnicell, Inc., and OncoCyte Corporation

Published
Jul 26, 2019
See More
See All Press Releases

Published

Published

ACRS Analyst Ratings

Data is currently not available
Consensus  

 

See all analyst research

Forecasts

SELECT THE TIMEFRAME :
Data is currently not available
 
   

Option Chain

Data is currently not available
 
 
 
 
 
 
 
See full OPTION CHAIN history
Data is currently not available

Key Executives
Name Title
Address: Phone:
Fundamentals

Ownership and SEC Filings

Historical

Download Data
Data is currently not available
 
   
See Full Historical Data See Historical NOCP

Active stocks by Dollar Volume

AMZN

Data is currently not available
AAPL

Data is currently not available
TSLA

Data is currently not available
INTC

Data is currently not available

Investors may trade in the Pre-Market (4:00-9:30 a.m. ET) and the After Hours Market (4:00-8:00 p.m. ET). Participation from Market Makers and ECNs is strictly voluntary and as a result, these sessions may offer less liquidity and inferior prices. Stock prices may also move more quickly in this environment. Investors who anticipate trading during these times are strongly advised to use limit orders.

  • Real-time Data is provided using Nasdaq Last Sale Data